Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Inclusion Criteria:

• Have signs and/or symptoms or documented diagnosis of Psoriatic Arthritis (PsA) forat least 6 months and currently fulfilling the classification of Psoriatic Arthritis (CASPAR) criteria.

• Have active PsA, defined as the presence of at least 3 of 68 tender joints and atleast 3 of 66 swollen joints.

• Have obesity, body mass index of ≥30 kilograms per meter squared (BMI ≥30 kg/m²) oroverweight (BMI ≥27 to <30 kg/m²) in the presence of at least 1 of theseweight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleepapnea, cardiovascular disease, or T2DM).

Exclusion Criteria:

Medical Conditions

• Have Type 1 Diabetes Mellitus (T1DM).

• Have insulin-treated Type 2 Diabetes Mellitus (T2DM).

• Have a prior or planned surgical treatment for obesity.

• Have a family or personal history of medullary thyroid carcinoma (MTC) or multipleendocrine neoplasia (MEN) syndrome type 2.

• Have active, or a history of inflammatory bowel disease (Crohn's or ulcerativecolitis).

• Have a diagnosis or history of malignant disease within the 5 years prior torandomization, with the following exceptions:

• basal cell or squamous epithelial carcinomas of the skin that have beenresected, with no evidence of metastatic disease for 3 years.

• cervical carcinoma in situ, with no evidence of recurrence within the 5 yearsprior to randomization.

• Have a serious disorder or illness other than PsA.

• Have a history of chronic or acute pancreatitis.

• Have any prior use of ixekizumab or tirzepatide.

• Diagnosis of other inflammatory arthritis, such as Rheumatoid Arthritis (RA),ankylosing spondylitis, reactive arthritis, gout, or enteropathic arthritis.

• Have a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) orglucagon-like peptide 1 (GLP-1) receptor agonists.